A French remote-monitoring company takes US growth equity to move beyond oncology, an Oxford blood-cancer spin-out funds its first human trials, and start-ups in Finland, Denmark and Paris raise fresh capital for power conversion, aftersales software and healthcare administration. Here are the five European tech stories that matter this Sunday.

1. Resilience Care raises €48m from PSG Equity to expand beyond French cancer care

Resilience Care has raised €48 million from US growth-equity firm PSG Equity as the sole investor in the round, taking total capital raised since 2021 above €105 million as it tries to copy its French oncology model in psychiatry, gastroenterology and other countries.

Les Echos reported the deal on 5 November, naming Marion Simon-Rainaud and Charlie Perreau as authors. The remote-monitoring company was developed with France's Gustave-Roussy cancer institute and founded in 2021 by Céline Lazorthes, who left during 2025, and Jonathan Benhamou, who now runs it alone. Benhamou told the paper the aim is to become "multipathologies, multipays" with France as the springboard, and that acquisitions will be used to speed the shift. A day later, CFNEWS said the digital remote-monitoring business generates nearly €20 million in revenue and described its doctrine as three countries and three pathologies. At least one funding tracker later listed the new round as €40 million rather than €48 million; Les Echos, the primary report, put the figure at €48 million.

Why it matters: Hospital-grade remote monitoring is one of the few European health-tech categories with a reimbursement path. A single US growth fund writing a cheque of this size, after the departure of a high-profile co-founder, is a test of whether the model can travel into new specialties and health systems.

Source: Les Echos (French)

2. Oxford spin-out Alethio Therapeutics raises $90m to take a blood-cancer antibody into human trials

Alethio Therapeutics, a University of Oxford spin-out, has raised an oversubscribed $90 million (£67 million) Series A co-led by Sofinnova Partners and RA Capital to advance its lead antibody, ATX-011, towards the first trials in patients with essential thrombocythaemia.

The Oxford Post reported on 6 November that the company announced the round on Thursday 5 November. Oxford Science Enterprises, a founding investor, joined alongside Cancer Research Horizons and the University of Oxford. Sofinnova's Graziano Seghezzi and RA Capital's Maxwell DeNies have joined the board. Alethio was founded by Oxford physician-scientists Adam Mead and Beth Psaila and incorporated in July 2021 as Alethiomics; Dr Rohit Batta is chief executive. ATX-011 is designed to bind a protein called G6B, which the company says is found on platelets and on the stem cells that drive myeloproliferative neoplasms, but not on healthy blood stem cells. Current treatments can control blood counts but are not aimed at those cells. The antibody has not yet been given to patients. The Oxford Post said Alethio is still in the laboratory and safety work required before a US Investigational New Drug filing, which it targeted for the first quarter of 2027, and that the new money is meant to carry ATX-011 through Phase 1/2a studies and support other programmes. European Biotechnology Magazine, writing on 5 November, put the round at about €80 million and said Batta expects enrolment to begin in the first half of 2028, subject to regulators.

Why it matters: This is one of the larger European biotech financings of the autumn, and it is still preclinical. An antibody that has only been tested in the laboratory and in animals will now have the cash to find out whether those results appear in people — or fail at the usual first hurdle.

Source: The Oxford Post

3. Finland's Vensum Power raises €9m to put software-defined converters into production

Vensum Power has raised €9 million in a Series A co-led by Lifeline Ventures, Larsen & Toubro Group and Eviny Ventures, taking total funding to €15.2 million so it can move its software-defined power converters into mass production in 2027 for EV charging, energy storage and DC microgrids, and then into AI data centres.

Tech.eu reported the round on 6 November. The Finnish company designs converters that are meant to keep high efficiency even when electrical loads swing quickly, cutting the electricity lost when power is changed into a form machines can use. Chief executive Peter Nisula told Tech.eu that in data centres "the question is no longer only how powerful the chips are, but how efficiently the used electricity actually reaches them." A Finnish note published the same day by the industry body Pääomasijoittajat said existing backers Grid.vc and Harjavalta Ventures also took part, and that the company, founded in 2018, employs about 20 people.

Why it matters: Grid connections, not just semiconductors, now cap how fast European AI capacity can grow. A small Finnish deep-tech team backed by an Indian industrial group and a Norwegian energy investor is betting that wasted conversion, not just missing megawatts, is the bottleneck operators will pay to fix.

Source: Tech.eu

4. Copenhagen's Claimlane raises €5.6m to send AI agents after broken products — and into the US

Claimlane has raised €5.6 million in a Series A from Verb Ventures, Skagerak Capital and Vendep Capital to build AI agents around each customer's warranties and supplier contracts and to expand in the United States, which the Danish company says is now its largest market for new customers.

TechSavvy reported the round on 5 November, citing the company's announcement. Claimlane's platform is meant to connect brands, retailers, suppliers and repair partners when a product fails, covering warranty decisions, repairs, replacements, refunds and supplier claims. Named customers include Skechers, Black Diamond, tonies and Hummel; the company told TechSavvy it sits on a network of more than 20,000 dealers and brands. It said US sales opportunities are up 150% year on year and that newly created pipeline value has doubled, and that chief executive and co-founder Anders Sommer has moved to Austin to lead the expansion. Tech.eu, which also covered the round the same day, said Verb Ventures led it. The agents are being built to assess cases against a customer's own policies, with people kept involved where judgement is needed, and to deepen expertise in electronics, furniture and outdoor equipment.

Why it matters: Aftersales is still a tangle of spreadsheets and bilateral emails, which is why brands treat it as a cost centre. A Copenhagen company using a US beachhead, rather than another European city, shows where it thinks the buyers willing to let software handle warranty decisions now sit.

Source: TechSavvy (Danish)

5. Paris start-up Granit raises €5m to automate healthcare billing inside existing software

Granit, founded in Paris in March 2026, has raised €5 million — €3.5 million of equity led by Seedcamp and €1.5 million of non-dilutive funding, including from Bpifrance — to run AI agents that check coverage, issue invoices, correct rejected claims and chase payers inside the software healthcare providers already use.

FrenchWeb reported the financing on 5 November. The company was founded by Jenny Mansour and Corneille Maréchal and says it is deployed in more than 250 facilities in France. It charges by usage, keeps human managers for unusual cases, and claims administrative time can fall by as much as 90%, a figure FrenchWeb noted came without a stated measurement scope. The money is earmarked for technical and commercial hiring, new medical specialties and first steps in several other European countries. Maddyness, in its 6 November weekly funding tally, recorded only the €3.5 million equity slice and listed Drysdale Ventures, Cleo Ventures, Kima Ventures, Re:rail and Purple Ventures alongside Seedcamp.

Why it matters: Most of a clinic's digital burden is not the consultation note; it is getting paid. An eight-month-old company raising a pre-seed of this size to sit on top of incumbent billing tools, rather than replace them, is a narrower — and more testable — bet than another clinical chatbot.

Source: FrenchWeb (French)